Tag Archives: Therasense

IPO Chat Channel: Inequitable Conduct – A Refresher & Update – April 23rd

Have findings of inequitable conduct due to egregious misconduct become more common post-Therasense or can a simple failure to disclose material prior art still lead to a finding of inequitable conduct? What are the possible consequences to both litigators and … Continue reading

Posted in Inequitable Conduct/Rule 56, Prior Art, Uncategorized | Tagged , , | Leave a comment

Therasense Puts A World Of (Antitrust) Hurt On 3M

Commentators who have declared inequitable conduct dead and buried should study TransWeb, LLC v. 3M Innovative Properties Co., App. No. 2014-1646 (Fed. Cir., Feb. 10 2016). {A copy can be found at the end of this post.] The decision demonstrates … Continue reading

Posted in Patent Eligible Subject Matter | Tagged , , , , , , , , , , , , | Leave a comment

Apotex Petitions Supreme Court to Review Therasense Standards

In Apotex, Inc. v. UCB, Inc., Appeal No. 2013-1674 (Fed. Cir. August 15, 2014) the court affirmed the district court’s ruling that one actor, Dr. Sherman, the chairman of Apotex had committed inequitable conduct by engaging in what the court … Continue reading

Posted in Inequitable Conduct/Rule 56 | Tagged , , , , , , , | Leave a comment

Takeaways from Seattle Summer 2014 Seminars

A guest post by Donald Chisum and Janice Mueller. In August 2014 the Chisum Patent Academy held two back-to-back seminars in its Seattle, Washington facility to discuss and debate current developments in patent law. Each roundtable seminar group was limited … Continue reading

Posted in Conferences and Classes | Tagged , , , , , , | Leave a comment